S
Salarius Pharmaceuticals
An oncology based biotechnology company
About Salarius Pharmaceuticals
Salarius Pharmaceuticals is a biotechnology company focused on developing innovative cancer treatments, particularly targeting epigenetic causes of sarcoma. The company operates in the biopharmaceutical market, primarily serving patients with rare and aggressive cancers. Salarius employs a research-driven business model, leveraging scientific advancements to create novel therapies. Revenue is generated through the development and commercialization of its proprietary drugs, as well as potential partnerships and grants. The company has been recognized for its contributions to oncology and has received significant funding, including an $18.7 million award from the Cancer Prevention and Research Institute of Texas (CPRIT).
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- Houston, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cancer Prevention and Research Institute of Texas (CPRIT)
Series B and later1 investor entered at this stage
Tech Coast Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Salarius Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Salarius Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.